Telomir Pharmaceuticals, trading on NASDAQ under the ticker TELO, has announced a preclinical breakthrough with its lead candidate, Telomir-1, in a genetic animal model of Wilson’s disease. This rare disorder, characterized by copper accumulation, saw significant symptom reversal in zebrafish models treated with Telomir-1. The drug demonstrated a 4- to 5-fold reduction in tremors, normalized movement behaviors, and halved liver copper levels, alongside improvements in organ histopathology and key liver biomarkers. These findings underscore Telomir-1's potential as a copper-regulating therapeutic, with the company planning to file its first Investigational New Drug (IND) application by the end of the year and commence human trials in 2026.
The implications of this development are profound for patients suffering from Wilson’s disease, a condition that currently has limited treatment options. The ability of Telomir-1 to address both neurological and organ-specific symptoms could revolutionize the management of this disease, offering a comprehensive treatment approach. Furthermore, this breakthrough highlights the potential of Telomir Pharmaceuticals' focus on longevity science, with Telomir-1's mechanism of action targeting the aging process at the cellular level. The success of Telomir-1 in preclinical trials not only brings hope to those affected by Wilson’s disease but also paves the way for future applications in other age-related and degenerative conditions.
